Onyx Bridge Wealth Group LLC Lowers Position in Bristol-Myers Squibb (NYSE:BMY)

Onyx Bridge Wealth Group LLC lessened its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 5.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,714 shares of the biopharmaceutical company’s stock after selling 269 shares during the period. Onyx Bridge Wealth Group LLC’s holdings in Bristol-Myers Squibb were worth $344,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. New Millennium Group LLC purchased a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at approximately $31,000. Clear Investment Research LLC purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $36,000. Western Pacific Wealth Management LP lifted its position in shares of Bristol-Myers Squibb by 878.6% during the 3rd quarter. Western Pacific Wealth Management LP now owns 548 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 492 shares in the last quarter. McClarren Financial Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $41,000. Finally, Heritage Wealth Management LLC purchased a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at approximately $44,000. Hedge funds and other institutional investors own 75.51% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of a number of recent analyst reports. Atlantic Securities increased their target price on Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, February 3rd. Morgan Stanley raised their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “underweight” rating in a report on Friday, February 3rd. StockNews.com began coverage on Bristol-Myers Squibb in a report on Thursday. They issued a “strong-buy” rating on the stock. Jefferies Financial Group began coverage on Bristol-Myers Squibb in a report on Monday, March 6th. They issued a “hold” rating and a $62.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on Bristol-Myers Squibb in a report on Tuesday, January 17th. They issued an “overweight” rating and a $95.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.69.

Insider Activity

In related news, EVP Ann Powell sold 11,183 shares of the firm’s stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $74.69, for a total transaction of $835,258.27. Following the completion of the transaction, the executive vice president now directly owns 23,043 shares in the company, valued at approximately $1,721,081.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Giovanni Caforio sold 240,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $74.65, for a total value of $17,916,000.00. Following the completion of the transaction, the chief executive officer now owns 236,104 shares in the company, valued at approximately $17,625,163.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction on Monday, February 6th. The stock was sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now owns 23,043 shares of the company’s stock, valued at approximately $1,721,081.67. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of Bristol-Myers Squibb stock opened at $66.53 on Friday. The firm has a market cap of $139.63 billion, a PE ratio of 22.55, a price-to-earnings-growth ratio of 1.46 and a beta of 0.46. The company has a quick ratio of 1.14, a current ratio of 1.25 and a debt-to-equity ratio of 1.13. Bristol-Myers Squibb has a 52 week low of $65.28 and a 52 week high of $81.43. The business’s fifty day simple moving average is $70.96 and its 200-day simple moving average is $72.91.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.71 by $0.11. The company had revenue of $11.41 billion during the quarter, compared to analyst estimates of $11.20 billion. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. Bristol-Myers Squibb’s revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.83 earnings per share. Equities analysts forecast that Bristol-Myers Squibb will post 8.06 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Stockholders of record on Monday, April 10th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, April 6th. This represents a $2.28 annualized dividend and a dividend yield of 3.43%. Bristol-Myers Squibb’s dividend payout ratio is currently 77.29%.

About Bristol-Myers Squibb

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.